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Obesity-induced inflammation contributes to multiple metabolic diseases. In this issue of Immunity, Lynch
et al. (2012) show that invariant natural killer T (iNKT) cells are enriched in adipose tissue and induce
anti-inflammatory pathways to confer protection against obesity.The incidence of obesity worldwide has
increased at an astounding rate in recent
decades and, as a result, obesity-related
diseases have become a major threat to
human health. Obesity-induced inflam-
mation is centrally involved in the patho-
genesis of numerous diseases, including
type 2 diabetes, atherosclerosis, hepa-
tosteatosis, and even some forms of
cancer. Immune cells have emerged
as pivotal mediators of the persistent
state of inflammation that drives obesity-
associated diseases. For instance, proin-
flammatory cytokines that are produced
by effector T cells and CD11c-expressing
M1 macrophages in the fat can cause
tissue damage and subsequent metabolic
dysfunction (Kanneganti and Dixit, 2012).
In contrast, anti-inflammatory cytokines
such as interleukin-4 (IL-4) and IL-10 that
are generated by regulatory T (Treg) cells,
CD206+CD11c M2 macrophages, and
eosinophils dampen adipose-tissue in-
flammation and maintain metabolic ho-
meostasis (Kanneganti and Dixit, 2012).
In this issue of Immunity, Lynch et al.
(2012) identify invariant natural killer T
(iNKT) cells as important negative regula-
tors of adipose-tissue inflammation and
obesity-associated disease. iNKT cells
constitute a distinct subset of lympho-
cytes that express a semivariant T cell
receptor (Va24-Ja18 in humans and
Va14-Ja18 in mice) and recognize lipid
antigens presented by the nonpolymor-
phic CD1d molecule (Godfrey and Kro-
nenberg, 2004). They are deployed as
part of the innate immune response and
rapidly respond to microbial and sterile
insults. Interestingly, iNKT cells are capa-
ble of potently producing both T helper 1
(Th1) (IFN-g) and Th2 (IL-4) cell-associ-
ated cytokines, and this dual functionality
enables them to play both pathogenic andimmunoregulatory roles. Proinflammatory
cytokine production by iNKT cells is
required to mount protective immunity
against numerous pathogens and tumors.
In contrast, IL-4 and IL-10 elicited by iNKT
cells have also been shown to suppress
autoimmune responses in type 1 diabetes
and multiple sclerosis.
In their previous studies, Lynch and
colleagues found that iNKT cells are
highly enriched in the adipose tissue of
lean individuals, whereas obesity is asso-
ciated with reduced numbers of periph-
eral iNKT cells (Lynch et al., 2009).
Following up on these observations, they
investigated the in vivo role of iNKT cells
in obesity-induced inflammation. Consis-
tent with their initial data in humans, they
show here that iNKT cells also constitute
a large fraction of the T cell population in
the fat pads of lean mice. Moreover,
obesity that is induced by either high fat
diet (HFD) or genetic ablation of leptin
(ob/obmice) results inmassive reductions
in iNKT cell numbers in the adipose tissue
and liver. Intriguingly, weight loss fol-
lowing bariatric surgery in morbidly obese
individuals and a return to a standard
fat diet (SFD) in overweight mice coin-
cides with marked increases in iNKT cell
numbers.
To elucidate the specific contributions
of iNKT cells in adipose-tissue inflamma-
tion and metabolic disease, Lynch et al.
(2012) investigated the development of
obesity-associated disease in two sepa-
rate iNKT cell-deficient mouse strains
(Ja18- and CD1d-deficient mice). The
absence of iNKT cells resulted in greater
weight gain and adipose-tissue expan-
sion in mice fed an HFD. Furthermore,
iNKT cell-deficient mice also developed
exacerbated fatty liver disease, insulin
resistance, and elevated blood glucoseImmunity 37, Selevels. iNKT cells do not appear to influ-
ence energy expenditure or appetite, as
weekly food consumption and circulating
leptin levels were similar between wild-
type and iNKT cell-deficient mice. Rather,
the absence of iNKT cells was found to
promote enhanced infiltration of inflam-
matory macrophages into the adipose
tissue of HFD-fed mice.
Lynch et al. (2012) further establish a
protective role for iNKT cells in obesity-
induced metabolic disease by showing
that the adoptive transfer of iNKT cells
into obese mice rapidly promotes weight
loss and causes dramatic reductions in
adipocyte size. iNKT cell transfer also
rescued metabolic dysfunction in obese
mice, as was exhibited by improved
glucose tolerance and insulin sensitivity.
To further underscore the central im-
portance of iNKT cells in restraining
adipose-tissue inflammation, they stimu-
lated obese mice with the prototypical
iNKT cell ligand alpha-galactocylcera-
mide (aGC) to expand and activate pre-
existing iNKT cells. In this model, one
injection of aGC was enough to potently
expand iNKT cells in the adipose tissue
and led to marked improvements in meta-
bolic parameters. The rescue of meta-
bolic disease following aGC treatment
corresponded with enhanced local ex-
pression of the anti-inflammatory cyto-
kines IL-4 and IL-10 by iNKT cells in the
adipose tissue (Figure 1). Neutralizing
both IL-4 and IL-10 during aGC stimula-
tion of obese mice resulted in impaired
glucose tolerance, which suggests that
iNKT cell-mediated protection during
obesity-induced metabolic disease is at
least partly dependent on these anti-
inflammatory cytokines.
In addition to the findings presented by
Lynch et al., multiple other groups haveptember 21, 2012 ª2012 Elsevier Inc. 447
Figure 1. iNKT Cells Dampen Adipose-Tissue Inflammation
In the lean state, iNKT cells are highly enriched in the adipose tissue and help to maintain normal metabolic function by limiting local inflammation. Obesity-
induced inflammation causes dramatic reductions in iNKT cell numbers in the adipose tissue and is associated with the enhanced recruitment of inflammatory
M1macrophages. Sustained inflammation that is mediated by inflammatory immune cells, including M1macrophages and effector T cells, causes dysregulation
of metabolic functions and can result in type 2 diabetes, hepatosteatosis, dyslipidemia, and cardiovascular disease. The activation and expansion of iNKT cells
following treatment with the prototypical iNKT cell agonist, aGC, provokes rapid weight loss and dampens adipose-tissue inflammation. Moreover, the resto-
ration of iNKT cell activity in obese mice results in improved insulin sensitivity and glucose tolerance. iNKT cell-mediated production of IL-4 and IL-10 contributes
to this protective effect by limiting the recruitment of inflammatory M1 macrophages and promoting the expansion of suppressive M2 macrophages in the
adipose tissue.
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iNKT cells in the regulation of obesity-
induced inflammation and metabolic
functions. There is general consensus
that iNKT cells are pivotal regulators of
adipose-tissue inflammation; however,
disagreement exists as to whether iNKT
cells exert pathogenic or suppressive
functions. In line with the findings de-
scribed by Lynch et al. (2012) in this issue,
Ji and colleagues have also concluded
that adipose-tissue-derived iNKT cells
are critically involved in limiting metabolic
inflammation (Ji et al., 2012). Both studies
show that aGC treatment is an effective
means of expanding iNKT cells in the
adipose tissue and results in improved
metabolic functions, including glucose
tolerance in obese mice. Moreover, both
groups suggest that iNKT cell-mediated
production of immunoregulatory cyto-
kines (IL-4 and IL-10) promotes protective
effects by limiting the expansion of in-
flammatory M1 macrophages and induc-
ing the polarization of suppressive M2
macrophages. A separate study also448 Immunity 37, September 21, 2012 ª2012proposed that iNKT cells are required for
maintaining normal metabolic function
under steady-state conditions (Schipper
et al., 2012). They showed that iNKT
cell-deficient mice are more susceptible
to insulin resistance on a standard diet.
In a similar fashion, Lynch et al. (2012)
demonstrate that iNKT cell-deficient
mice exhibit metabolic perturbations on
a standard diet. In their study, however,
they do not report improvements in insulin
sensitivity, but rather show that the lack of
iNKT cells promotes enhanced weight
gain and adipocyte expansion. It should
be noted that pathogenic roles for iNKT
cells in obesity-induced inflammation
have also been described. In a recent
publication, it was suggested that iNKT
cell activation in the adipose tissue of
HFD-fed mice causes impairment of
metabolic functions through the release
of proinflammatory cytokines and the
recruitment of other pathogenic immune
cells (Wu et al., 2012). Thus, both sup-
pressive and inflammatory functions have
been assigned to iNKT cells in obesity.Elsevier Inc.One possibility is that differences in
microbiota between the mouse facilities
used in these studies contributed to the
discordant results. Indeed, commensal
gut bacteria have been described to pro-
minently influence iNKT cell function and
also affect obesity-associated disease
pathogenesis (Turnbaugh et al., 2006).
Regardless, it is clear from this collec-
tion of studies that iNKT cells are central
regulators of adipose-tissue inflammation
and obesity-induced disease and that
there are numerous important questions
that still remain to be addressed. One of
the next great challenges in the field will
be identifying the factors that regulate
iNKT cell numbers in the adipose tissue.
It is still unclear what events cause
the striking loss of iNKT cells during
adipose-tissue expansion. The immune-
mediated inflammation and metabolic
stress that are associated with adipose-
tissue expansion are known to dis-
rupt normal lipid metabolism and result
in ‘‘lipid spillover’’ (Thompson et al.,
2010). Furthermore, prolonged iNKT cell
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overall iNKT cell numbers (Parekh et al.,
2005). Thus, it is possible to envision a
scenario wherein altered and/or en-
hanced lipid antigen presentation in
the obese state can provoke changes
in iNKT cell activation, turnover, and
homeostasis.
A growing list of immune cells have
been recently identified as contributing
to maintaining normal metabolic homeo-
stasis and restraining adipose-tissue in-
flammation in the face of metabolic
distress (Kanneganti and Dixit, 2012).
Future investigation of the reciprocal
crosstalk between these cells in the
adipose-tissue microenvironment will be
imperative for gaining a more complete
understanding of immunometabolism.
Work in other disease models has shown
that iNKT cells can affect disease out-
comes by orchestrating changes to other
immune cells, including antigen-present-
ing cells and CD4+ T cells (Godfrey and
Kronenberg, 2004); thus, iNKT cells may
dampen obesity-induced inflammation
through their regulation of other cell
populations.Current approaches to treat obesity,
including dietary and lifestyle changes,
have done little to curtail the ongoing
global obesity epidemic. Novel therapeu-
tics are desperately needed for treatment
of the array of obesity-induced metabolic
disorders that are on the rise. Lynch
et al. (2012) present compelling evidence
that iNKT cell-inducing strategies may
provide an effective means of thwarting
the obesity epidemic. aGC has already
been approved for use in cancer patients
and has proven to be an effective and
safe means of enhancing iNKT cells
numbers. Future clinical studies in obese
patients are warranted for determining
whether iNKT cell-enhancing agents
can promote weight loss and improve
metabolic functions.REFERENCES
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